NCT03894540View on ClinicalTrials.gov

Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

PHASE1TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 22, 2019

Primary Completion Date

December 21, 2020

Study Completion Date

December 21, 2020

Conditions
Solid Tumor
Interventions
DRUG

IPN60090

Oral capsules given daily

DRUG

pembrolizumab

An intravenous solution in single-use vial to be diluted for infusion.

DRUG

paclitaxel

An intravenous solution in single-use vial to be diluted for infusion.

DRUG

IPN60090 single administration

Oral capsules given once

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY